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We retrospectively investigated the incidence of pancreatic ductal adenocarcinoma among patients with intraductal papillary
mucinous neoplasms of the pancreas. Based on imaging in 195 such patients, we chose surgery as initial treatment for 54,
and periodic evaluation over 6 to 192 months (mean, 52) for 141. In 6 of the 141 patients observed for intraductal papillary
mucinous neoplasm (4.2%), pancreatic ductal adenocarcinoma developed. Further, careful monitoring for cancer occurrence
in the remnant pancreas proved essential in the surgical resection group; 2 of 26 patients (7.7%) subsequently developed
pancreatic ductal adenocarcinoma in the remnant pancreas, at 41 months and 137 months after surgery. Serial observation of
patients with intraductal papillary mucinous neoplasms by contrast-enhanced computed tomography or magnetic resonance
cholangiopancreatography therefore is critical, whether or not surgical treatment initially was performed.
1.Introduction
Asymptomatic patients with intraductal papillary mucinous
neoplasms (IPMN) of the pancreas are common in Japan,
as these tumors are detected by widely conducted ultra-
sonographic mass surveys. Since IPMNs include several
pathologic types including invasive carcinoma, carcinoma
in situ, adenoma, and hyperplasia, one needs to distin-
guish benign from malignant lesions to avoid unnecessary
surgery. On the other hand, in 2002, Yamaguchi et al.
[1] reported an important relationship between IPMN and
ductal adenocarcinoma of the pancreas: IPMN is a strong
riskfactorforpancreaticcancer.Ourgroup[2]hass uggest ed
that serial observations should be performed at every 6-
month intervals in patients with IPMN of the branch duct
type. We presently investigated usefulness of intraductal
ultrasonography (IDUS) as a precise diagnostic modality for
IPMN and also examined long-term incidence of pancreatic
ductaladenocarcinoma(PDAC)associatedwithIPMNofthe
branch duct type.
2. Patients andMethods
We treated 208 patients with PDAC from 1990 to 2009
at our hospital. The treatment was surgical in 64 patients.
We analyzed them in terms of age, gender, tumor staging,
resection rate, and association with IPMN.
We also treated 195 patients with IPMN at our hospital
over the same period. We diagnostically evaluated IPMN
using ultrasonography, endoscopic ultrasonography (EUS),
intraductal ultrasonography (IDUS), endoscopic retrograde
cholangiopancreatography(ERCP),contrast-enhancedcom-
putedtomography(CECT),andmagneticresonancecholan-
giopancreatography (MRCP). We used mainly EUS and
IDUS in deciding about surgical treatment in patients with
IPMN [3]. We performed IDUS using a miniature ultrasonic
probe with frequency of 20MHz, developed by Olympus
Medical Systems (Tokyo, Japan). We classiﬁed 4 images
(Figure 1) obtained by EUS and/or IDUS as type I, with no
mural nodule; type II, with a mural nodule elevated less than
5mm;typeIII,withamuralnoduleatleast5mm;ortypeIV,2 ISRN Gastroenterology
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Figure 1: Classiﬁcation of IPMN of the branch duct type into 1 to 4 types based upon images obtained by EUS and/or IDUS: type I, with
no mural nodule; type II, with a mural nodule-elevated lesion less than 5mm; type III, with a mural nodule elevated at least 5mm; or type
IV, solid tumor with a mixture of high and low echogenicity in the pancreatic parenchyma.
solid tumor with a mixture of high and low echogenicity
in the pancreatic parenchyma [4]. Type III suggested intra-
ductal papillary mucinous adenoma (IPMA), while type IV
suggested intraductal papillary mucinous adenocarcinoma
(IPMC). We recommended surgical treatment for patients
with type III or IV images, and follow-up examination at 6-
month intervals for patients with type I or II.
According to the indications outlined above, we per-
formed surgical treatment for 54 patients, and periodic eval-
uations including ultrasonography, CECT, and/or MRCP,
over 6 to 192 months (mean, 52) for 141 patients. We ana-
lyzed patients with IPMN in terms of age, gender, pathologic
ﬁndings, and incidence of PDAC.
3. Results
3.1. Pancreatic Ductal Adenocarcinoma. Sixty-four patients
with PDAC underwent surgical treatment; the resection rate
was only 30.1%. Men accounted for 42 patients and women
for 22. Ages ranged from 33 to 80 years (mean, 52). In 144
patients with PDAC, surgical treatment was not performed
because of advanced tumor stage. Eighty-eight of these
patients were men and 60 were women; ages ranged from 47
to 94 years (mean, 71). Patients undergoing resection were
younger than the others (P<0.001). Only 11 tumors were
considered small (less than 2cm in diameter), including 4
T1 cases (limited to the pancreas). According to the TNM
classiﬁcation, 6 surgery patients were at stage I; 6, stage II,
18, stage III; and 34, stage IV. Of these 64 surgical patients
with PDAC, 4 (6.3%) had associated IPMN; all 4 underwent
resection (2, stage I; 1, stage III; and 1, stage IV).
3.2. Case 1: A Patient with PDAC and IPMN of the Branch
Duct Type. In a 55-year-old man, ultrasonographic mass
screening detected a multilocular cystic lesion in the head of
the pancreas; ERCP revealed dilation of the main pancreatic
duct and dilation of the branch duct. Pancreatoduodenec-
tomy was performed; pathologic examination disclosed
IPMA (Figure 2). Ultrasonography and noncontrast CT 137
months after surgical treatment detected enlargement of the
remnantpancreas(Figure 3).Thepatientdeclinedadditional
resection and died 11 months later. Pathologic examination
at autopsy disclosed tubular adenocarcinoma of the pancreas
(Figure 4).
3.3.IntraductalPapillaryMucinousNeoplasmsofthePancreas.
Surgery was performed in 54 patients with IPMN. Twenty-
nine patients were men and 25 were women. Age ranged
from 26 to 79 years (mean, 62). Pathologic examinations
identiﬁedhyperplasiain5patients;adenomain28,including
6 in whom it was associated with PDAC; and adeno-
carcinoma in 21 (10 carcinomas in situ and 11 invasiveISRN Gastroenterology 3
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Figure 2: Case 1: (a) Pancreatogram showing dilation of the
main pancreatic duct and cystic dilation of the branch duct. (b)
Pathologic examination disclosed IPMA. Haematoxylin and eosin
high magniﬁcation.
Figure 3: Case 1: A noncontrast CT 137 months after surgical
treatment demonstrating enlargement of the remnant pancreas.
carcinomas). Of the 11 PDAC considered small, 3 were
detected in patients with IPMN. Among 28 patients with
IPMA who underwent surgical treatment, 18 were men and
10 were women; ages ranged from 26 to 79 years (mean,
64). In 2 of 28 patients with IPMA (7.1%), pathologic
examinations demonstrated PDAC at a site other than that
of IPMA. In another 2 of 26 patients with IPMA but no
synchronous PDAC (7.7%), PDAC subsequently developed
in the remnant pancreas, at 41 and 137 months after surgery.
Among141patientswithIPMNwhounderwentperiodic
evaluation over 6 to 192 months (mean, 52), 61 were men
and 80 were women. Ages ranged from 35 to 88 years
(a)
(b)
Figure 4: (a) Macroscopic ﬁndings at autopsy. (b) Pathologic
examination disclosed tubular adenocarcinoma of the pancreas.
Haematoxylin and eosin, high magniﬁcation.
(mean, 61). In 6 of 141 patients with IPMN (4.2%), PDAC
developed during serial observation periods (mean duration
of observation, 6 to 103 months (mean, 47). Three of these
patients underwent surgical treatment; the other 3 did not
because of advanced tumor stage (2 patients in stage I, and 4
in stage IV).
3.4. Case 2: A Patient with IPMN Who Developed PDAC
during Observation. In a 79-year-old woman, a noncontrast
CT detected a small multilocular cystic lesion in the head of
the pancreas (Figure 5). ERCP showed dilation of the main
pancreatic duct, but not cystic lesions, and EUS identiﬁed
a multilocular cystic lesion in the head of the pancreas
(but none in the tail). Results of cytologic examination
of pancreatic juice were considered class 3. Contrast CT
6 months after the ﬁrst CT detected a small tumor as a
low-density area in the tail of the pancreas (Figure 6). EUS
showed this as a hypoechoic mass, 20mm in diameter, in the
tail of the pancreas (Figure 7). The pathologic diagnosis was
well-diﬀerentiated tubular pancreatic adenocarcinoma with
no extension beyond the pancreas (stage I; Figure 8).
4. Discussion
IPMN ﬁrst was described by Ohhashi et al. [5] in 1982 as
a mucin-producing pancreatic tumor. Several other publica-
tions followed [6–11], and an international consensus state-
ment was issued in 2006 [12]. Reported patients with IPMN4 ISRN Gastroenterology
Figure 5: Case 2: Noncontrast CT showing a small multilocular cystic lesion in the head of the pancreas and no lesions in the tail of the
pancreas.
Figure 6: Case 2: Contrast CT 6 months after the ﬁrst CT
demonstrating a small tumor as a low-density area in the tail of the
pancreas.
usually were symptomatic, especially when the tumor was
malignant [13]. In Japan, however, ultrasonographic mass
screening for digestive cancers conducted nationwide; so
patients with IPMN are detected in an asymptomatic condi-
tion. Appropriate therapeutic indications for asymptomatic
patients diagnosed by mass screening are as important as
correct diagnoses.
Recent advances in diagnostic imaging have been
helpful determining therapeutic procedures. CECT using
multidetector-row-computed tomography (MDCT) can
detect a mural nodule in a cyst, making it useful in
diﬀerential diagnosis between benign and malignant lesions
[14]. Development of MRCP promises reliable delineation
of communications between the main pancreatic duct and
cystic lesions. MRI allows more conﬁdent assessment of
morphology of small cysts than MDCT, but accuracy of
the two imaging techniques for characterization of most
cysts is comparable [15] .E U Si sr e p o r t e dt ob ear e l i a b l e
method for diﬀerential diagnosis of IPMN [16–18]. Pre-
operative diagnosis of the malignant potential of IPMN is
of growing importance because pancreatic surgery has its
complications [19]. We reported usefulness of IDUS for
diﬀerential diagnosis of IPMN between benign and malig-
nant lesions [2]. In unpublished study, we performed IDUS
Figure 7: EUS disclosing a small hypoechoic mass, 20mm in
diameter, in the tail of the pancreas.
for 17 patients with IPMN treated by surgical resection;
elevations of lesions measured by IDUS were 3.8 ± 1.3mm
for IPMA but were signiﬁcantly greater for IPMC (8.3 ±
3.0mm, P<0.05). Corresponding elevations measured at
pathologic examination were 2.6 ± 1.0a n d6 .5 ± 2.8mm,
respectively (P<0.01). Elevations of lesions determined by
IDUS were less than 5mm in 6 of 7 IPMA. We suggested
that patients with a papillary nodule showing elevation
of 5mm more should be treated surgically. We usually
used IDUS in determining the therapeutic approach for
IPMN.
Clinicians should note the possibility of coexisting or
subsequently developing PDAC in patients with IPMA of
the branch duct type. When Yamaguchi et al. [1]r e p o r t e d
the relationship between IPMN and ductal adenocarcinoma
of the pancreas, their 7 patients with both tumor types
represented 9.2% of the 76 patients with IPMN and 9.1%
of the 77 patients with PDAC. All 7 IPMNs were of the
branch duct type with a mean diameter of 3.0cm. InISRN Gastroenterology 5
Figure 8: Pathologic ﬁndings diagnostic of well-diﬀerentiated tubular pancreatic adenocarcinoma, not extending beyond the pancreas.
Haematoxylin and eosin: low and high magniﬁcation.
our series, of 141 serially observed patients with IPMN, 6
(4.2%) developed PDAC. Vigilance for cancer occurrence in
the remnant pancreas after surgical resection is necessary.
Among 26 of our patients, 2 (7.7%) subsequently developed
PDAC in the remnant pancreas, after 41 and 137 months.
Maguchi et al. [20] reported that PDAC developed in 7
of 349 patients with IPMN of the branch duct type (2%)
during observation periods ranging from 1 to 16.3 years
(median, 3.7). Sawai et al. [21] reported EUS followed-up
for at least 2 years (median 59 months) in 103 patients with
IPMN of the branch duct type; 6 patients (5.8%) developed
pancreatic cancers during follow-up, speciﬁcally IPMC in 4
and PDAC in 2 patients. On the other hand, our recurrence
rate following partial pancreatectomy for benign IPMN was
similar to that reported by the Mayo Clinic: 5 of 60 patients
(8%) with a median follow-up duration of 37 months [22].
Patients with IPMA treated by resection indeed require long-
term follow-up.
When IPMN is detected, EUS is recommended for diﬀer-
entialdiagnosis.However,howandwhenshouldserialobser-
vationsbemadeinpatientswithIPMN?Diagnosticprecision
ofEUSdependsupontheskillofindividualendoscopists.On
the other hand, MRCP and MDCT show high accuracy in
classifying cysts into mucinous and nonmucinous categories
and perform similarly in estimating histologic aggressiveness
[15]. We therefore recommend performing MRCP or CECT
with MDCT every 6 months. If changes in morphology of
cystic lesions occur, EUS and/or IDUS should be performed
again.Furtherstudiesshouldbetterdeﬁnechoiceofmodality
and duration of serial observation.
EarlydetectionofPDACinpatientswithoutsymptomsis
the most important goal for improving prognosis of patients
with pancreatic cancer. In addition to the ordinary risk
factors including IPMN, individuals with a family history of
PDAC and hereditary syndromes are expected to be entered
into the screening protocol [23].
5. Conclusions
EUS and IDUS are recommended as a further evaluation
for IPMN detected by mass screening. Because IPMN is
an important risk factor for PDAC, clinicians should be
awareofthepossible coexistence ordevelopment ofPDAC in
patients with IPMN, especially the branch duct type. Serial
observation of patients with IPMN by MDCT or MRCP
is necessary whether or not initial surgical treatment is
performed.
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